Investor Resources Home

At Heron, our mission is to improve the lives of patients by developing best-in-class medicines that address unmet medical needs. We are developing novel, patient-focused solutions that apply our innovative science and technologies to already-approved pharmacological agents.
HRTX (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$19.38
Change (%) Stock is Up 0.11 (0.57%)
Volume358,334
Data as of 08/26/16 4:00 p.m. ET
Refresh quote

Corporate Presentation

DateTitle
08/10/16
Download Documentation SUSTOL® Approval – August 10, 2016

Recent News

More >>
DateTitle 
08/10/16Heron Therapeutics Announces U.S. FDA Approval of SUSTOL® (granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and VomitingPrinter Friendly Version
08/08/16Heron Therapeutics Reports Second Quarter 2016 Financial Results and Recent Corporate ProgressPrinter Friendly Version
08/02/16Heron Therapeutics Enters into Loan Agreement for Up to $100 MillionPrinter Friendly Version
08/01/16Heron Therapeutics Reports Positive Top-Line Results from Phase 2 Studies of HTX-011 for Management of Post-Operative PainPrinter Friendly Version

Upcoming Events

More >>

There are currently no events scheduled.

Data provided by NASDAQ. Minimum 15 minutes delayed.